(Received for publication July 21, 1998) The plasminogen/plasmin system is involved in a variety of physiological and pathological processes requiring localized proteolysis, such as fibrinolysis, inflammation, tissue remodeling, ovulation, tumor Circulating, native plasminogen (Plg) with NH2-terminal Glu1 (Glu-Plg) is a single-chain glycoprotein with multiple functional domains, which consist of an NH2-terminal peptide (NTP), five homologous kringle domains and a trypsin-like serine protease domain6,7).
Glu-Plg exhibits a tight spiral structure because of an intramolecular interaction between a lysine residue in the NTP and the aminohexyl site of kringle 58,9) giving rise to resistance to activation by Plg activators and low
In a local site where Plg is activated, plasmin hydrolyzes Glu-Plg to yield a truncated form of Plg called Lys-Plg13,14), which lacks NTP and adopts a relaxed conformation. Lys-Plg has a high susceptibility to activation and a high affinity to fibrin and cellular receptors9,15). Plg binding to fibrin and cell surface receptors localizes and facilitates the Plg/plasmin system16).
We have recently isolated a fungal triprenyl phenol metabolite (designated staplabin; Fig. 1 ) from a culture of Stachybotrys microspora as an activator of Glu-Plg binding to fibrin and monocytoid U937 cells17). Staplabin induces a conformational change in both Glu-Plg and Lys-Plg to allow them to bind fibrin and to be activated by Plg activators with higher efficiency18). Later, S. microspora was found to produce minor staplabin analogs, two of which were isolated and shown to be far less active than staplabin 19). In the present study, four more analogs (Fig. 1 Human Glu-Plg and Lys-Plg were purchased from Enzyme Research Laboratories, USA. Human fibrinogen, human thrombin, bovine serum albumin and S-2251 (H-D-Val-Leu-Lys-p-nitroanilide) were obtained from Sigma, USA. Staplabin was isolated from a culture of S. microspora IFO30018 as described previously17). Urokinase-type Plg activator (two-chain form) was obtained from JCR Farmaceuticals, Japan, and aprotinin from CosmoBio, Japan. Carrier-free Na125I was purchased from Amersham. The compositions of buffers were: buffer A, 50mM Tris-HCl, 100mM NaCl and 0.01% (wt/vol) Tween 80, pH 7.4; buffer B, 20mM sodium phosphate and 150mM NaCl, pH 7.4; buffer C, Hanks' balanced salt solution containing 1mg/ml bovine serum albumin and 50mM HEPES, pH 7.4.
Fermentation
Production of SMTPs
The producing strain S. microspora IFO 30018
(obtained from the Institute for Fermentation, Osaka, Japan) was subcultured on potato glucose agar slants. For the production of SMTP-3, a medium containing the following was used: 30g glucose, 10g soybean meal, 3g meat extract, 3g peptone, 3g yeast extract, 0.5g
were produced in a medium containing 20g glucose, 5g 7H2O and 0.1g CB442 in 1 liter of reverse osmotic water (pH 5.5). A loopful of a slant culture was inoculated into a 500-ml Erlenmeyer flask containing 100ml of medium, shaker at 180rpm. A 1-ml portion of the seed culture was inoculated into a 500-mi Erlenmeyer flask containing 100 ml of medium and the flask was incubated as above for 12 days for production of SMTP-3 and for 11 days for other SMTPs.
Radioiodination of Plg and Fibrinogen
Both Glu-Plg and Lys-Plg were radioiodinated using
Chloramine-T and Na125I as described by Miles and cpm/ng. Over 97% of the radioactivity was precipitable upon treatment with 10% trichloroacetic acid. Fibrinogen was labeled by the iodine monochloride method21) ment with thrombin, approximately 80% of the radioactivity of 125I-fibrinogen were incorporated into the clot.
Determination of Plasminogen Activation
Plg activation was assayed either by measuring initial velocity for plasmin generation using a chromogenic substrate for plasmin or by determining the rate for conversion of 125I-Plg to 125I-plasmin using SDSpolyacrylamide gel electrophoresis (SDS-PAGE)18). In the former assay, 50nM Plg and 0.1mM S-2251 were to 60 minutes. From the slope of the plots of A405 nm versus t2, the velocity of plasmin generation was calculated23). In the latter assay, 50nM 125I-Plg was incubated with urokinase (30 units/ml for 125I-Glu-Plg and 2 units/ml for 125I-Lys-Plg) and aprotinin (1000 Aprotinin was used to inhibit plasmin activity that forms Lys-Plg during incubation of Glu-Plg. After incubation SDS, 3.6% (wt/vol) dithiothreitol and 0.08% (wt/vol) SDS-PAGE24) on a 10% gel in triplicate. After fixing and drying, the gel was exposed to an X-ray film at ing to Plg and the light and heavy chains of plasmin were excised from the gel and counted for radioactivity in a Determination of 125I-Plasminogen Binding to Fibrin
The assay was performed as described previously17,22 The UV spectrum was measured in MeOH on a model 320 spectrometer (Hitachi, Japan) and the IR spectrum on an IR-810 spectrometer (JASCO, Japan) with NaCl.
The FAB mass spectrum was taken on an SX-102A spectrometer (JEOL, Japan) using glycerol as a matrix.
on an EX-270 spectrometer (JEOL) at 270 MHz (for 1H) and 68 MHz (for 13C). The optical rotation was measured on a model DIP-360 (JASCO) in MeOH.
Results

Isolation
of SMTP-3 SMTP-3 was produced as a minor metabolite along with staplabin and SMTP-1 and -2. The combined culture supernatant (4.9 liters) was applied to a Diaion HP-20 liters of water, the column was developed with 4.9 liters of 50% aqueous MeOH. The 50% MeOH eluate was concentrated to give 11.7g of an oily residue. The residue was suspended with 1 liter of chloroform-MeOH (4:1), and the suspension was centrifuged to obtain supernatant, which was concentrated to give 6.4g of a residue. This material was applied to a silica gel column oped with a mixture of chloroform and MeOH ( In the modified medium, several metabolites including SMTP-4, -5 and -6 were accumulated as well as staplabin. The combined culture supernatant (9.15 liters) was extracted with 2-butanone (once with 9 liters and twice with 4.5 liters). The organic layer was concentrated, giving 3.89g of an oily residue. The residue was applied developed successively with a mixture of dichloromethane and MeOH (98: 2, 95: 5 and then 90: 10; 3.9 liters each). SMTP-4 and -5 were found in the dichloromethane -MeOH (95: 5) fraction, which were concentrated to give 946mg of a residue. The residue was subjected to preparative HPLC on an Inertsil was developed with n-hexane -EtOH (93: 7) at a rate of 9.9 ml/minute. The fractions containing SMTP-4 (retenyielding 15.9 and 12.5mg of respective purified compounds. SMTP-6 was found in the dichloromethaneMeOH (90:10) fraction in the silica gel column chromatography. The fraction was dried in vacuo, giving 845 mg of a residue. This material was subjected to preparative HPLC on an Inertsil PREP-ODS column The physico-chemical properties of SMTPs are summarized in Table 1 . The four SMTPs were soluble in chloroform, MeOH and DMSO. The molecular formulae were established from the NMR and HRFAB-MS spectra. The UV and IR spectra of the SMTPs were similar to those of staplabin 17). In 1H and 13C NMR spectra of the four SMTPs (Tables 2  , 3 ), signals corresponding to the ring structure and the 4, 8-dimethyl-3, 7-nonadienyl side chain of staplabin were found. The presence of such structures was further confirmed by the 1H-1H COSY, 13C-1H COSY and HMBC spectra. The structural difference between staplabin and the four SMTPs was found in the substituent at position 2 of the lactam ring. In the NMR spectra, the four analogs were shown to lack carboxybutyl signals found in staplabin but had the following signals: a carbonyl, a nitrogen-bearing methine and an oxygen-bearing methylene for SMTP-3; a carbonyl, a nitrogen-bearing methine, an aliphatic methylene, an olefinic quaternary carbon and five olefinic methines for SMTP-4; a carbonyl, a nitrogen-bearing methine, an aliphatic methylene, an aliphatic methine and two methyls for SMTP-5; a carbonyl, a nitrogen-bearing 
Effects on Plg Activation
The effects of SMTPs on Plg activation were first examined by determining the conversion of 125I-Plg to 125I-plasmin. As shown in Fig. 3A , the rate of urokinase-catalyzed conversion of 125I-Glu-Plg to 125I -plasmin was markedly elevated by SMTP-4 , -5 and -6 at concentrations ranging from 0 .15 to 0.4 mM, while the effect of SMTP-3 was not significant at concentrations up to 0.45 mM. Lys-Plg, which adopts a relaxed conformation, is more sensitive to activation than is Glu-Plg, and significant conversion to plasmin occurred at a lower concentration of urokinase (see Materials and Methods). SMTP-4, -5 and -6, but not SMTP-3, were also active in enhancing the conversion of 125I-Lys-Plg 3B). However, the magnitude of the enhancement was significantly lower than that observed with Glu-Plg THE JOURNAL OF ANTIBIOTICS Table 2 . NMR spectral data for SMTP-3 and -4.
activation. In control incubations in the absence of urokinase, SMTPs showed no effect on the conversion of both Glu-Plg and Lys-Plg. Since SMTP-3 was inactive in enhancing Plg activation, its activity was not evaluated further.
Next, urokinase-catalyzed Plg activation was determined by measuring the generation of plasmin activity using a chromogenic plasmin substrate, S-2251. In the activation of Glu-Plg, SMTP-4, -5 and -6 were shown to enhance 2-to 12-fold the generation of plasmin activity at concentrations ranging from 0.1 to 0.25mM (Fig. 4A) . As the concentration of staplabin required for elevating 2-fold Glu-Plg activation was 0.4 mM, these analogs are at least three times as active as staplabin.
The activation of Lys-Plg was also significantly elevated by the three -5 were rather moderate (Fig . 4B) . These results were similar to the results obtained with the assay determining the conversion of Plg to plasmin, indicating that plasmin formed in the presence of SMTPs was functionally active. In the absence of urokinase, SMTPs showed no effect on the hydrolysis S-2251 by Plg.
Effects on Plg Binding to Fibrin
The fibrin binding of 125I-Plg was assayed in the presence of SMTPs at a concentration of 0.3 mM. The Table 3 . NMR spectral data for SMTP-5 and -6. binding of 125I-GluPlg was enhanced 3.5-to 4.6-fold by SMTP-4, -5 and -6 (Fig. 5A) . Similarly, the binding of 125I-Lys-Plg was also elevated by these analogs , while the effects were less prominent than the effects on 125I-GluPlg binding (Fig . 5B) . Although staplabin has been shown to be active in elevating binding of both mM) 17,18), it was inactive at 0.3mM. The activation of Glu-Plg (A) and Lys-Plg (B) was determined by measuring the generation of plasmin activity in the presence of the indicated concentration of SMTPs and staplabin. Each value represents the 125-fibrin with urokinase and Glu-Plg in the presence of SMTPs at a concentration 0.25 mM (Fig. 6 ). The level of fibrinolysis was significantly elevated by SMTP-4, -5 and -6 (2.3-fold, 1.9-fold and 2.7-fold, respectively). Under these conditions, staplabin caused a slight activation of fibrinolysis. In the absence of urokinase, Staplabin enhances both activation and fibrin binding of Plg. These effects are attributable to a conformational change of Plg induced by stapiabin18). Like the effect of staplabin, the effects of SMTP-4, -5 and -6 on these activities are more prominent with Glu-Plg, which has a tight structure, than with Lys-Plg, which adopts a more relaxed conformation. Therefore, the enhancement of Plg activation and fibrin binding of Plg by these analogs may be related to a conformational change in the Plg molecule. As shown in the previous studies, staplabin action quenches at higher concentrations18 
Effects on Fibrinolysis
